What is PF-07914705 Influenza saRNA used for?

PF-07914705 Influenza saRNA is indicated for Influenza.

Who makes PF-07914705 Influenza saRNA?

PF-07914705 Influenza saRNA is developed by Pfizer.

What development phase is PF-07914705 Influenza saRNA in?

PF-07914705 Influenza saRNA is FDA-approved (marketed).

What is the generic name of PF-07914705 Influenza saRNA?

pf-07914705-influenza-sarna is the generic (nonproprietary) name of PF-07914705 Influenza saRNA.

Last reviewed 2026-04-20 · How we verify

PF-07914705 Influenza saRNA (pf-07914705-influenza-sarna)

Pfizer · FDA-approved active Quality 35/100

PF-07914705 Influenza saRNA is a marketed drug by Pfizer Inc. for Influenza. It has generated $21.2B in revenue. The mechanism of action is not specified. It has 1 trial and 0 publications. This drug is a first-in-class treatment for Influenza.

At a glance

Generic name	pf-07914705-influenza-sarna
Sponsor	Pfizer
Drug class	RNA-based therapy
Target	influenza virus
Therapeutic area	Immunology
Phase	FDA-approved

Approved indications

Influenza

Common side effects

No common side effects on file.

Drug interactions

Atazanavir
Darunavir
Lopinavir
Ritonavir
Saquinavir
Tipranavir

Key clinical trials

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-07914705 Influenza saRNA CI brief — competitive landscape report
PF-07914705 Influenza saRNA updates RSS · CI watch RSS
Pfizer portfolio CI